This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's What We Expect From AbbVie's Immunology Segment in Q4
by Sundeep Ganoria
ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.
JNJNegative Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
Bull of the Day: Eli Lilly (LLY)
by Andrew Rocco
Eli Lilly has solidified itself as a global pharma titan. With leading drugs and a massive obesity market, Lilly is poised to be a juggernaut for years to come.
RHHBYNegative Net Change LLYPositive Net Change INCYPositive Net Change
biotechs pharmaceuticals
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies
by Zacks Equity Research
GSK's bepirovirsen hit primary endpoints in two phase III trials, boosting hopes for a functional cure in chronic hepatitis B patients.
GSKPositive Net Change CRMDPositive Net Change IONSPositive Net Change KROSPositive Net Change
biotechs medical pharmaceuticals
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
by Zacks Equity Research
Monte Rosa shares surge 45% after interim phase I data show that MRT-8102 drives deep NEK7 degradation and reduces sharp inflammation markers.
FOLDPositive Net Change CRMDPositive Net Change GLUENegative Net Change INDVPositive Net Change
biotechs
KRYS Stock Surges 57% in a Year: More Upside Potential in 2026?
by Zacks Equity Research
Shares of Krystal Biotech soar 57% in a year as strong Vyjuvek uptake and steady pipeline progress continue to push the stock higher.
FOLDPositive Net Change CRMDPositive Net Change KRYSPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Is LLY's Ventyx Deal Another Attempt at Diversification Beyond GLP-1?
by Ahan Chakraborty
Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space intensifies.
PFEPositive Net Change NVONegative Net Change LLYPositive Net Change VTYXNegative Net Change
biotechnology biotechs medical pharmaceuticals
RVMD Stock Hits a Record High on Rumored Takeover Interest
by Zacks Equity Research
Revolution Medicines shares jump nearly 29% to a record high after a WSJ report said AbbVie showed takeover interest, a claim the pharma giant later denied.
LLYPositive Net Change AMGNPositive Net Change ABBVPositive Net Change RVMDPositive Net Change
biotechs medical pharmaceuticals
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study
by Zacks Equity Research
Exelixis teamed with Natera on the phase III STELLAR-316 study testing zanzalintinib in resected stage II/III colorectal cancer. Stock gains.
RHHBYNegative Net Change EXELPositive Net Change FOLDPositive Net Change CRMDPositive Net Change NTRAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up
by Zacks Equity Research
DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.
SNYPositive Net Change BIIBPositive Net Change DNLIPositive Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies
by Zacks Equity Research
Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.
AMGNPositive Net Change CRMDPositive Net Change EXASPositive Net Change ALMSPositive Net Change
biotechs
FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug
by Zacks Equity Research
Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.
ALKSPositive Net Change CRMDPositive Net Change IPSCPositive Net Change INDVPositive Net Change
biotechs
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know
by Zacks Equity Research
Outlook Therapeutics stock plunges 67% in a week after the FDA issues a third CRL rejecting its ONS-5010 BLA for wet AMD, again seeking confirmatory data.
FOLDPositive Net Change CRMDPositive Net Change OTLKNegative Net Change INDVPositive Net Change
biotechnology biotechs medical pharmaceuticals
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
by Kinjel Shah
Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.
SLNONegative Net Change IRWDPositive Net Change NKTRPositive Net Change RIGLPositive Net Change MRKRPositive Net Change
biotechs pharmaceuticals
Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline
by Zacks Equity Research
AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.
AZNPositive Net Change JNJNegative Net Change PFEPositive Net Change AMGNPositive Net Change
biotechs
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH
by Zacks Equity Research
Altimmune shares rally 16.52% after the FDA grants Breakthrough Therapy status to pemvidutide for MASH.
ALTPositive Net Change ANIPNegative Net Change CRMDPositive Net Change INDVPositive Net Change
biotechs
Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase?
by Zacks Equity Research
CELC shares surge as NDA filing and strong phase III data boost optimism around gedatolisib's potential.
FOLDPositive Net Change ANIPNegative Net Change CRMDPositive Net Change CELCPositive Net Change
biotechs
ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now?
by Sundeep Ganoria
ANI Pharmaceuticals' shares are up 21% in six months as strong 2025 results, repeated earnings beats and higher guidance highlight momentum in rare diseases.
TEVAPositive Net Change ANIPNegative Net Change AMRXPositive Net Change
biotechs medical
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study
by Zacks Equity Research
Zenas BioPharma tanks nearly 52% despite positive INDIGO study data where obexelimab cut IgG4-RD flare risk by 56% and met all key endpoints.
ANIPNegative Net Change CRMDPositive Net Change EXASPositive Net Change ZBIONegative Net Change
biotechs
Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings?
by Kanishka Das
Galafold drives over 80% of Amicus product revenues, with $371.5M in the first nine months of 2025 sales as investors await Q4 sales performance.
SNYPositive Net Change TEVAPositive Net Change FOLDPositive Net Change
biotechs
MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine
by Zacks Equity Research
Moderna jumps after filings seeking approval for its mRNA-1010 flu vaccine across major markets, with plans to launch the shot for older adults next year.
SNYPositive Net Change GSKPositive Net Change MRNAPositive Net Change
biotechs medical messenger-rna vaccines
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma
by Zacks Equity Research
Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.
BMYPositive Net Change INCYPositive Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?
by Ahan Chakraborty
Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Three Genomics Stocks Worth Tracking This Year
by Ekta Bagri
Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.
ILMNPositive Net Change BEAMPositive Net Change PACBPositive Net Change WVEPositive Net Change CRSPPositive Net Change SANAPositive Net Change
biotechnology biotechs cell-therapy gene-therapy genetics genomics medical pharmaceuticals thematic
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?
by Zacks Equity Research
KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.
REGNPositive Net Change SNYPositive Net Change GILDPositive Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals